Dear [NAME],

As a patient in [NAME OF STATE], I would like cell-free DNA (cfDNA)-based noninvasive prenatal screening (NIPS) available to me during pregnancy. I applaud [NAME OF PLAN] for covering this prenatal screening test for its high-risk patients to detect common fetal chromosomal abnormalities. However, there is compelling clinical evidence that NIPS is a medically-appropriate screening procedure for all pregnant women who want prenatal chromosomal screening—regardless of risk factors, income, age, or geographic location.

These tests screen for more chromosomal conditions than other screening options, and it has both the highest detection rate and the lowest false positive rate for any prenatal screening test. The lower false positive rates mean that I am much less likely to be referred for an unnecessary invasive procedure if I have NIPS during pregnancy instead of a traditional screening test. Additionally, having accurate screening would allow me to plan and prepare for any health concerns identified in my baby, for my delivery and with my health care providers and my family.
I understand that more than 100 million lives in the United States already have coverage for NIPS for all pregnancies, regardless of risk.

I hope you will consider the information provided here and update your medical policy to also provide access to NIPS as a medically appropriate option for all your pregnant enrollees.